Placeholder Banner

BIO Submits Comments on Medicare CY 2020 Part D Draft Call Letter

March 20, 2019

BIO submitted comments on the Centers for Medicare and Medicaid Service’s Advance Notice of Methodological Changes for Calendar Year (CY) 2020 for Medicare Advantage (MA) Capitation Rates, Part C and Part D Payment Policies and 2020 Draft Call Letter.

BIO supports CMS’s commitment to improving the quality and delivery of care in the MA and Part D programs. It’s critically important to ensure these programs advance patient access to timely and appropriate treatment, particularly for prescription drugs and vaccines. BIO provided comments on how to update and clarify the policies and provide greater access to patients while mitigating OOP costs.

Download Full Comments Below
FINAL BIO CY 2020 Draft Call Letter Comments 1 March 2019
See the full comment letter here:
Discover More
March 18, 2020 FDA Docket No: FDA-2019-D-4964: FDA Draft Guidance on Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products Dear Sir/Madam: BIO thanks FDA for developing this additional guidance on…
March 15, 2020 Re: Docket No. FDA–2019-D-4752: FDA Draft Guidance, Pediatric Study Plans for Oncology Drugs: Questions and Answers BIO appreciates FDA’s efforts to develop a document that outlines questions and answers pertaining to Pediatric…
In the wake of the COVID-19 outbreak, the Biotechnology Innovation Organization (BIO) joins 111 industry groups across sectors in a letter to federal, state and local lawmakers supporting uniform definitions of "critical infrastructure" as outlined…